has been cited by the following article(s):
|
[1]
|
Gram-positive infections in special populations. Expert view on the role of dalbavancin
Expert Review of Anti-infective Therapy,
2025
DOI:10.1080/14787210.2025.2477196
|
|
|
|
|
[2]
|
Long-Acting Lipoglycopeptide Antibiotics (Dalbavancin and Oritavancin) for the Treatment of Endotipsitis in a Patient With Cirrhosis
Infectious Diseases in Clinical Practice,
2022
DOI:10.1097/IPC.0000000000001082
|
|
|
|
|
[3]
|
Pharmacokinetic/Pharmacodynamic Analysis the Probability of Target Attainment of Posaconazole against Mucorales Species in Patients with Mucormycosis
Pharmacology & Pharmacy,
2020
DOI:10.4236/pp.2020.115007
|
|
|
|